https://bio.nikkeibp.co.jp/atcl/news/p1/25/03/17/13089/
https://academic.oup.com/bbb/article-abstract/89/3/459/7923509?redirectedFrom=fulltext&login=false
https://www.mdpi.com/2072-6643/17/1/101
Ezaki Glico has announced that in its bacterial library it had discovered Lactobacillus helveticus GCL1815 strain that activates the human body’s immune system. Clinical research has confirmed that it also reduces subjective cold symptoms.
The company searched through a library of approximately 10,000 strains of lactic acid bacteria to find a strain with high functionality that (1) increases the production of immunoglobulin (Ig) A, (2) activates dendritic cells, and (3) increases the production of interleukin (IL-12), a cytokine that activates natural killer (NK) cells and T cells.
In a randomized, double-blind, placebo-controlled study on 192 healthy adults, participants were asked to take GCL1815 strain or a placebo for 8 weeks, and were asked to complete a questionnaire survey on subjective cold symptoms such as fever, fatigue, lethargy, runny nose, stuffy nose, and phlegm. As a result, the cumulative number of people and days with subjective cold symptoms during the study period was significantly lower in the GCL1815 strain group, at 938 days compared to 1116 days in the control group. In fact, dendritic cells were significantly more activated in the GCL1815 group than in the control group.
The company plans to develop products that use the GCL1815 strain.
